# nsclc (podcasts) — RSS Amplifier Recent posts from the 3 feeds in the RSS Amplifier directory that cover nsclc. Page: Feed: --- ## [Iberdomide](https://soundcloud.com/user-650920398/iberdomide) _2026-08-20 · OncoPharm_ CELMoDs are here, but are they here to stay? CELMoD/IMiD review article: https://doi.org/10.1080/17474086.2024.2382897 Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm [Listen](https://feeds.soundcloud.com/stream/2385251205-user-650920398-iberdomide.mp3) ## [LCC: Grace Under Pressure: Navigating Burnout and Loss in Oncology](https://soundcloud.com/lungcancerconsidered/lcc-grace-under-pressure) _2026-08-18 · Lung Cancer Considered_ In this episode of Lung Cancer Considered, host Dr. Narjust Florez is joined by Dr. Mark Lewis and Dr. Michael Maddaus for a candid conversation about physician wellness, burnout, grief, and resilience. Drawing from their personal and professional experiences, they explore the hidden emotional toll of caring for patients with cancer, the limitations of the “just be more resilient” mindset, and the… [Listen](https://feeds.soundcloud.com/stream/2375432939-lungcancerconsidered-lcc-grace-under-pressure.mp3) ## [LCC Advances in ALK+ Cancer in Cantonese](https://soundcloud.com/lungcancerconsidered/lcc-advances-in-alk-cancer-in) _2026-08-14 · Lung Cancer Considered_ As part of IASLC’s ongoing series of Lung Cancer Considered podcasts in world languages, Dr. Molly Li moderates a discussion in Cantonese with Dr. Tony Mok, Dr. Chao Zhang, and Dr. Wen-Zhao Zhong. The discussion reviews advances in ALK+ non-small cell lung cancer (NSCLC). [Listen](https://feeds.soundcloud.com/stream/2375065340-lungcancerconsidered-lcc-advances-in-alk-cancer-in.mp3) ## [Kidney Cancer in a Nutshell](https://soundcloud.com/user-650920398/kidney-cancer-in-a-nutshell) _2026-08-13 · OncoPharm_ Overview of renal cell carcinoma Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm [Listen](https://feeds.soundcloud.com/stream/2381254023-user-650920398-kidney-cancer-in-a-nutshell.mp3) ## [Small Cell Lung Cancer and CINV Updates](https://soundcloud.com/user-650920398/small-cell-lung-cancer-and) _2026-08-06 · OncoPharm_ This week's episode covers some updates in small cell lung cancer, chemotherapy-induced nausea/vomiting (CINV), SC administration of isatuximab, and Lu-177 vipivotide tetraxetan. Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm [Listen](https://feeds.soundcloud.com/stream/2376827312-user-650920398-small-cell-lung-cancer-and.mp3) ## [Treating Advanced Thymic Cancers](https://soundcloud.com/lungcancerconsidered/iaslc-management-of-thymic) _2026-08-04 · Lung Cancer Considered_ Thymic epithelial tumors are rare but complex thoracic cancers that require specialized diagnosis and multidisciplinary management. In this episode of Lung Cancer Considered, Dr. Stephen Liu is joined by Dr. Nicolas Girard and Dr. Erica Pietroluongo to discuss the diagnosis, staging, and treatment of thymoma and thymic carcinoma, including current standards of care, evolving systemic therapies,… [Listen](https://feeds.soundcloud.com/stream/2365317965-lungcancerconsidered-iaslc-management-of-thymic.mp3) ## [Zidesamtinib & PPIs in Pacific](https://soundcloud.com/user-650920398/zidesamtinib-ppis-in-pacific) _2026-07-30 · OncoPharm_ A new drug is approved for ROS1 NSCLC after a prior TKI (with some data in patients after 2 TKIs). Zidesamtinib...easy for you to say. Also, a post hoc analysis of PACIFIC provides some of the best evidence yet of the detrimental effect (?) of PPI use prior to ICI use. Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm [Listen](https://feeds.soundcloud.com/stream/2370746021-user-650920398-zidesamtinib-ppis-in-pacific.mp3) ## [FDA Approval: Zidesamtinib and ROS1 NSCLC](https://soundcloud.com/lungcancerconsidered/fda-approval-zidesamtinib-and) _2026-07-28 · Lung Cancer Considered_ Patients with ROS1-positive NSCLC have a new treatment option following the FDA approval of zidesamtinib for those previously treated with a ROS1 tyrosine kinase inhibitor. In this episode, Dr. Stephen Liu, Dr. Alexander Drilon, and Dr. Rosario Charo Garcia Campelo discuss the ARROS1 trial results, the drug's efficacy and safety profile, CNS activity, and where zidesamtinib may fit into current… [Listen](https://feeds.soundcloud.com/stream/2367726437-lungcancerconsidered-fda-approval-zidesamtinib-and.mp3) ## [Gedatolisib et al](https://soundcloud.com/user-650920398/gedatolisib-et-al) _2026-07-23 · OncoPharm_ This week's pod covers some brief updates comparing the timelines of the FDA approvals for daraxonrasib vs. enfortuamb vedodin + pembrolizumab, before devoting the rest of the time to the new approval of gedatolisib, a PIK3CA inhibitor, with fulvestrant and maybe palbociclib if you feel like it for metastatic breast cancer in the 2nd line. Oh, in patients WITHOUT PIK3CA mutations. Download the… [Listen](https://feeds.soundcloud.com/stream/2366762669-user-650920398-gedatolisib-et-al.mp3) ## [Rewriting the Playbook: Cellular Therapy and Vaccines for ALK-Positive Lung Cancer](https://soundcloud.com/lungcancerconsidered/iaslc-cell-therapy-and) _2026-07-21 · Lung Cancer Considered_ How could cellular therapies and cancer vaccines transform the future of treatment for ALK-positive lung cancer? Host Dr. Narjust Florez sits down with Dr. Vincent Lam and Dr. Carmen Mecca to explore the latest research, the science driving these innovative approaches, and what these advances could mean for patients and the future of precision oncology. Key Topics Covered: • ALK-positive lung… [Listen](https://feeds.soundcloud.com/stream/2359653311-lungcancerconsidered-iaslc-cell-therapy-and.mp3) ## [Retro Grid Dungeon Crawler (Sponsored)](https://crawlproof.com/a/Wug85gs3vXvX) _2026-07-21 · **Sponsored**_ Retro grid movement with first-person combat, loot and skill-tree progression. ## [Kausik Ray, MD, MPhil (Cantab), FMedSci - Altering the Disease Trajectory in Patients With and at High Risk of Atherosclerotic Cardiovascular Disease: Ensuring Best Practices for Identification and Management](https://peervoice.com/VUR860) _2026-07-20 · PeerVoice Heart & Lung Audio_ Kausik Ray, MD, MPhil (Cantab), FMedSci - Altering the Disease Trajectory in Patients With and at High Risk of Atherosclerotic Cardiovascular Disease: Ensuring Best Practices for Identification and Management [Listen](https://peervoice.com/140202828VUR.mp3?ProjectNumber=140202828&Promocode=861&AudienceID=PV) ## [Endurance Part 2](https://soundcloud.com/user-650920398/endurance-part-2) _2026-07-16 · OncoPharm_ Did lenalidomide maintenance in multiple myeloma just get limited to 2 years? Endurance Trial, Part 2: https://www.nejm.org/doi/full/10.1056/NEJMoa2600157 Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm [Listen](https://feeds.soundcloud.com/stream/2362244609-user-650920398-endurance-part-2.mp3) ## [A Decade of CAR-T, Ocra-T, & POLARGO](https://soundcloud.com/user-650920398/a-decade-of-car-t-ocra-t) _2026-07-09 · OncoPharm_ We are a decade into the CAR-T era, and what to long term outcomes look like with tisagenlecleucel in B-cell lymphomas? Orca-T is approved, an allogenic cocktail of stem & progenitor cells, Tregs, and then conventional T-cells. Neato. Polar-Go! or PolARGo? And the concept of T-cell "stemless" is intriguing with possibilities: DOI: 10.1056/NEJMcibr2601002 Learning Oncology… [Listen](https://feeds.soundcloud.com/stream/2356422722-user-650920398-a-decade-of-car-t-ocra-t.mp3) ## [IASLC - Your First Faculty Job](https://soundcloud.com/lungcancerconsidered/iaslc-your-first-faculty-job) _2026-07-07 · Lung Cancer Considered_ Starting your first faculty position can be both exciting and overwhelming. In this episode of Lung Cancer Considered, host Dr. Narjust Florez is joined by Dr. Arthi Sridhar to discuss the transition from fellowship to independent practice, sharing practical insights on navigating clinical responsibilities, building professional relationships, balancing personal and professional priorities, and… [Listen](https://feeds.soundcloud.com/stream/2344938464-lungcancerconsidered-iaslc-your-first-faculty-job.mp3) ## [Carel le Roux, MBChB, MSc, PhD - Beyond BMI: Transforming Modern Weight Management for Heart, Kidney, and Metabolic Health](https://peervoice.com/VAC860) _2026-06-29 · PeerVoice Heart & Lung Audio_ Carel le Roux, MBChB, MSc, PhD - Beyond BMI: Transforming Modern Weight Management for Heart, Kidney, and Metabolic Health [Listen](https://peervoice.com/140202789-2VAC.mp3?ProjectNumber=140202789-2&Promocode=861&AudienceID=PV) ## [Breast Cancer Updates and T-Cell Stemness](https://soundcloud.com/user-650920398/breast-cancer-updates-and-t) _2026-06-25 · OncoPharm_ This week we discuss a new approval for pabociclib in HER2-positive disease based on the PATINA trial as well as the use of sacituzumab govitecan + pembrolizumab in TNBC, recently approved based on the ASCENT04/KEYNOTED19 trial. And the concept of T-cell "stemless" is intriguing with possibilities: DOI: 10.1056/NEJMcibr2601002 Learning Oncology Companion:… [Listen](https://feeds.soundcloud.com/stream/2346846131-user-650920398-breast-cancer-updates-and-t.mp3) ## [Game Changers & Hard Truths: Dr. Balazs Halmos Unfiltered](https://soundcloud.com/lungcancerconsidered/leading-with-purpose-lessons) _2026-06-23 · Lung Cancer Considered_ In this episode of Lung Cancer Considered, Dr. Balazs Halmos reflects on a career at the forefront of thoracic oncology, sharing the pivotal moments, lessons learned, and hard truths that have shaped modern lung cancer care. Guest: Balazs Halmos, MD, MS Professor of Medicine Associate Director, Clinical Science Montefiore Einstein Comprehensive Cancer Center [Listen](https://feeds.soundcloud.com/stream/2317080770-lungcancerconsidered-leading-with-purpose-lessons.mp3) ## [Updates on capivasertib, belzutifan, talquetamab, & durvalumab](https://soundcloud.com/user-650920398/updates-on-capivasertib) _2026-06-18 · OncoPharm_ Lots of bite-size updates in this episode. Capitello-281: capivasertib + abiraterone (+ prednisone + ADT) Adjuvant Belzutifan + Pemroblizumab is FDA approved Durvalumab approved with BCG for non-muscle invasive bladder cancer Insightful commentary: https://doi.org/10.1200/JCO-25-02670 Talquetamab + Durvaluamb - a new safety signal? Learning Oncology Companion:… [Listen](https://feeds.soundcloud.com/stream/2342058656-user-650920398-updates-on-capivasertib.mp3) ## [Welcome to Seoul: 2026 World Conference on Lung Cancer (WCLC) Preview](https://soundcloud.com/lungcancerconsidered/welcome-to-seoul-2026-world) _2026-06-12 · Lung Cancer Considered_ This episode of Lung Cancer Considered provide a preview of the upcoming IASLC 2026 World Conference on Lung Cancer in Seoul, South Korea this September. Key topics covered include WCLC26 highlights - Multidisciplinary, WCLC26 deadlines and information about Seoul. Guests: Myung-Ju Ahn, MD, PhD Distinguished Professor Section of Hematology-Oncology, Department of Medicine Hanyang University… [Listen](https://feeds.soundcloud.com/stream/2332621490-lungcancerconsidered-welcome-to-seoul-2026-world.mp3) ## [ASCO '26](https://soundcloud.com/user-650920398/asco-26) _2026-06-11 · OncoPharm_ ASCO 2026 is a wrap, and we needed an extra week to digest it all! Here the review list: 1. RASolute 302 - daraxonrasib and its standing ovation 2. MajesTEC-9 - 2L teclistamab in multiple myeloma in patient population 100% exposed to CD-38 targeting drugs 3. Initsmeran autogene + pembrolizumab in resected melanoma. Only a Phase 2 study, but super promising and exciting use of personalized medicine… [Listen](https://feeds.soundcloud.com/stream/2337006764-user-650920398-asco-26.mp3) ## [Snapshot Showdown on Google Play (Sponsored)](https://crawlproof.com/a/PbDXoUzs0iOY) _2026-06-11 · **Sponsored**_ Available on Google Play for Android devices. ## [ASCO 2026 Highlights – Part 2: Emerging Immunotherapy Strategies in Lung Cancer](https://soundcloud.com/lungcancerconsidered/asco-2026-highlights-part-2) _2026-06-09 · Lung Cancer Considered_ In Part 2 of the ASCO 2026 Highlights series, hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by Dr. Julie Brahmer and Dr. Solange Peters to discuss some of the most notable immunotherapy advances presented at the 2026 ASCO Annual Meeting. The conversation explores emerging data for PD-1/VEGF and PD-L1/VEGF bispecific antibodies, the growing role of antibody-drug conjugates in combination… [Listen](https://feeds.soundcloud.com/stream/2335068584-lungcancerconsidered-asco-2026-highlights-part-2.mp3) ## [ASCO 2026 Highlights – Part 1: Landmark Advances in Targeted Therapy](https://soundcloud.com/lungcancerconsidered/lcc-2026-asco-highlights-part) _2026-06-05 · Lung Cancer Considered_ In this Part 1 of 2 ASCO 2026 Highlights episodes, hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by Dr. Alice Shaw and Dr. Jonathan Goldman to review some of the most impactful targeted therapy data presented at the 2026 ASCO Annual Meeting. The discussion explores the practice-changing LIBRETTO-432 trial in early-stage RET-positive NSCLC, long-term outcomes with lorlatinib in… [Listen](https://feeds.soundcloud.com/stream/2333316569-lungcancerconsidered-lcc-2026-asco-highlights-part.mp3) ## [Anjali Tiku Owens, MD - Contemporary Data, Differentiation, and Decision-Making in Hypertrophic Cardiomyopathy: A Guide to Cardiac Myosin Inhibition for the Managed Care Professional](https://peervoice.com/ZRT860) _2026-05-18 · PeerVoice Heart & Lung Audio_ Anjali Tiku Owens, MD - Contemporary Data, Differentiation, and Decision-Making in Hypertrophic Cardiomyopathy: A Guide to Cardiac Myosin Inhibition for the Managed Care Professional [Listen](https://peervoice.com/140202767-2ZRT.mp3?ProjectNumber=140202767-2&Promocode=861&AudienceID=PV) ## [Xin Cheng, MD, PhD - Seeking Solutions in Secondary Stroke Prevention: The Latest Inquiries and Insights on Factor XIa Inhibition](https://peervoice.com/FBM860) _2026-04-29 · PeerVoice Heart & Lung Audio_ Xin Cheng, MD, PhD - Seeking Solutions in Secondary Stroke Prevention: The Latest Inquiries and Insights on Factor XIa Inhibition [Listen](https://peervoice.com/140202483FBM.mp3?ProjectNumber=140202483&Promocode=861&AudienceID=PV) ## [Jonathan W. Goldman, MD / Misty Dawn Shields, MD, PhD - The Emerging Nuances of Extensive-Stage SCLC Treatment: Individualizing Care in the Immunotherapy Era](https://peervoice.com/KBA860) _2026-03-06 · PeerVoice Heart & Lung Audio_ Jonathan W. Goldman, MD / Misty Dawn Shields, MD, PhD - The Emerging Nuances of Extensive-Stage SCLC Treatment: Individualizing Care in the Immunotherapy Era [Listen](https://peervoice.com/140202752KBA.mp3?ProjectNumber=140202752&Promocode=861&AudienceID=PV) ## [Melanie J. Davies, CBE, MBChB, MD, FMedSci / Linong Ji, MD - Managing the Cost of Type 2 Diabetes: The Impact of Effective Use of Established Therapies](https://peervoice.com/XZR860) _2026-02-04 · PeerVoice Heart & Lung Audio_ Melanie J. Davies, CBE, MBChB, MD, FMedSci / Linong Ji, MD - Managing the Cost of Type 2 Diabetes: The Impact of Effective Use of Established Therapies [Listen](https://peervoice.com/540200030XZR.mp3?ProjectNumber=540200030&Promocode=861&AudienceID=PV) ## [Ira Goldberg, MD - Mastering the Fundamentals of Care for Chylomicronemia: Following the Patient Care Pathway From Differential Diagnosis to Modern Management](https://peervoice.com/URW860) _2026-01-14 · PeerVoice Heart & Lung Audio_ Ira Goldberg, MD - Mastering the Fundamentals of Care for Chylomicronemia: Following the Patient Care Pathway From Differential Diagnosis to Modern Management [Listen](https://peervoice.com/140202468URW.mp3?ProjectNumber=140202468&Promocode=861&AudienceID=PV) ## [Ira Goldberg, MD - The Expanding Treatment Landscape for Familial Chylomicronemia Syndrome: Exploring New Options and Opportunities](https://peervoice.com/NNA860) _2025-12-31 · PeerVoice Heart & Lung Audio_ Ira Goldberg, MD - The Expanding Treatment Landscape for Familial Chylomicronemia Syndrome: Exploring New Options and Opportunities [Listen](https://peervoice.com/140202815NNA.mp3?ProjectNumber=140202815&Promocode=861&AudienceID=PV) ## [John E. Anderson, MD / Richard J. Auchus, MD, PhD - Hypercortisolism and Difficult-to-Treat Cardiometabolic Disease: Therapeutic Developments and Clinical Advances Driving Meaningful Improvement in Patient Outcomes](https://peervoice.com/FTR860) _2025-12-23 · PeerVoice Heart & Lung Audio_ John E. Anderson, MD / Richard J. Auchus, MD, PhD - Hypercortisolism and Difficult-to-Treat Cardiometabolic Disease: Therapeutic Developments and Clinical Advances Driving Meaningful Improvement in Patient Outcomes [Listen](https://peervoice.com/140202695FTR.mp3?ProjectNumber=140202695&Promocode=861&AudienceID=PV) ## [Code Faster with Clear Tutorials (Sponsored)](https://crawlproof.com/a/vT3iFigvA924) _2025-12-23 · **Sponsored**_ Short, step-by-step coding videos you can follow along ## [Erwan Donal, MD, PhD / Nina Ajmone Marsan, MD, PhD - At the Cutting Edge of ATTR-CM: How Can We Leverage Advances in Multimodality Cardiac Imaging and Artificial Intelligence to Modernise Diagnosis and Monitoring?](https://peervoice.com/EPK860) _2025-12-16 · PeerVoice Heart & Lung Audio_ Erwan Donal, MD, PhD / Nina Ajmone Marsan, MD, PhD - At the Cutting Edge of ATTR-CM: How Can We Leverage Advances in Multimodality Cardiac Imaging and Artificial Intelligence to Modernise Diagnosis and Monitoring? [Listen](https://peervoice.com/140202523EPK.mp3?ProjectNumber=140202523&Promocode=861&AudienceID=PV)